The plant virus cowpea mosaic virus (CPMV) is an efficient carrier of foreign peptides for the generation of strong humoral immune responses. Peptides derived from both viruses and bacteria are strongly immunogenic when displayed on the surface of CPMV and elicit high titres of peptide-specific antibody. However, the protective effects of antibodies generated using bacterial epitopes in this system have yet t o be demonstrated. In this study the ability of chimaeric virus particles (CVPs) t o afford protection against bacterial infection was assessed. Immunization of outbred mice with CPMV expressing a peptide derived from outer-membrane protein F of Pseudomonas aeruginosa (CPMV-PAE5) generated high titres of P. aeruginosa-specif ic IgG that opsonized the bacteria for phagocytosis by human neutrophils and afforded protection upon challenge with t w o different immunotypes of P. aeruginosa in a model of chronic pulmonary infection. When examined 8 d after challenge, CVP-immunized mice had fewer severe lung lesions and fewer bacteria in their lungs compared t o mice immunized with wild-type virus. Different levels of protection were seen with CPMV-PAE5 when Freund's or alum adjuvants were used. These studies highlight the ability of CVPs t o generate protective immunity against infectious disease agents.
INTRODUCTION
Although live attenuated bacterial (Everest et al., 1995) and viral (Resnick et al., 1995; Rose & Evans, 1991; Sutter & Moss, 1992) vaccines as well as naked DNA vaccines (Montgomery et al., 1994) induce stronger and longer-lasting immune responses than conventional killed/subunit vaccines, even in the absence of adjuvant, there are safety concerns over the use of these vaccines (Vlacha et al., 1996; Klinman et al., 1997; WHO, 1990 ).
In particular, persistence or reversion to virulence of the live vaccine strains and integration of,*che naked DNA vaccine into the host chromosome are major concerns. To circumvent these potential problems, more effective inactive vaccines are being developed through modification of proteins or peptides by polymerization (Reed et al., 1997) , lipidation (Deprez et al., 1996) , oxidation/ reduction (Apostolopoulos et al., 1995) and encapsulation (Lovgren et al., 1990) . The immunogenicity of proteins can also be enhanced by coupling them to carrier molecules or bacterial proteins (Zhang et al., 1996; Jahn-Schmid et al., 1997) , or by producing them in the form of particulate virus-like particles (Adams et al., 1987; Ball et al., 1998) . Furthermore, the use of more effective adjuvants for both mucosal and systemic delivery has resulted in increased immunogenicity of non-replicating vaccines (Gupka & Siber, 1995 ; Elson & Dertzbaugh, 1994) .
In an effort to produce effective non-replicating vaccines, we have been examining the vaccine potential of a plant virus, cowpea mosaic virus (CPMV), genetically engineered (Usha et al., 1993 ; Porta et al., 1994) to express and display foreign peptides on its surface. In this presentation system, termed EPICOAT, peptides of up ~zl., 199.5, 1996; Buratti et al., 1998) . Also, another EPICOAT vaccine, presenting a peptide from the VP2 protein o f canine parvovirus, was shown to protect mink froin a lethal challenge with the canine-parvovirusrelated mink enteritis virus (Dalsgaard et al., 1997) . This w:is the first cknionstriition of an experimental vaccine p rod 11 ced e xc 1 us i ve 1 y i n p 1 ;i n t s con fe r r i rig p rot ec t i o n in the target animnl iigiiinst a viral disease.
More recently, we h~v e shown that peptides from b r i c t e r i r i 1 p rot e i n s a re a 1 so h i g h 1 y i m m u t i og e n i c w h e t i displriyed o n CI'MV. A CPMV- (FD) immunotype 2 (FD2) strain (described below). In a second study using the wtCPMV i n alum, CPMV-PAES in alum and CPMV-PAES in FCA/FIA groups, and an identical immunization regimen, mice were challenged with the FD4 strain. 111 a follow-up experiment, a wtCPMV in FCA/FIA and a CPMV-PAES in FCA/FIA group were challenged with the FD4 strain, and the results combined with those of the in it i a 1 ex per i men t .
ELISA for detection of P. aeruginosa-specific serum antibody. Pooled sera from each of the groups were examined for titres of IgG antibodies against P. aerugittosa FD2 and FD4 by ELISA as described previoiisly (Hughes et al., 1992; Staczek et al., 1998) . Briefly, plates (Dynatech; Immunlon 1) were coated with a suspension of whole P. aeruginosa (FD2 or FD4) cells prepared according to the method of Abdillahi & Poolman (1987) . Dilutions of sera were incubated on the bacteriacoated plates and bound antibody was detected with alkaline- Assay for opsonic activity of antisera. The ability of pooled antisera from CPMV-PAE5-immunized groups to mediate the uptake of P. aeruginosa cells by human polymorphonuclear leucocytes (PMNs) was compared with the ability of wtCPMV-immunized mouse sera to do likewise. As a positive control, sera pooled from 30 mice immunized with O M protein F (Gilleland et af., 1988) were compared to pooled NMS. The assay was performed as described previously (Gilleland et al., 1992) . The FD immunotype 2 and 4 strains were used in the assays. Briefly, bacterial cells were mixed with undiluted heat-inactivated sera and incubated with gentle shaking at 37 "C for 30 min. Human whole blood was added to the mixture and incubated for a further 30 min at 37 "C. After incubation of the blood with the bacteria and antisera, the mixture was fixed onto slides and stained with Giemsa stain. Each slide was examined microscopically and the number of bacterial cells contained within the first 50 isolated, intact PMNs encountered was determined for each reaction mixture. The assay was performed twice for each o f the pooled antisera so that a total of 100 PMNs were counted for each of the antisera. The mean number ( + s D ) of bacterial cells per PMN was then calculated. The statistical significance of the differences noted between groups was evaluated using the unpaired Student's t-test, with P 6 0.05 considered significant.
Challenge of mice with P. aeruginosa. Mice were challenged by using a model of chronic pulmonary infection with P. aeruginosa (Gilleland et al., 1988; Staczek et al., 1998) . Two weeks after the final immunization, the mice were challenged with agar beads containing P. aeruginosa cells of either the FD2 or FD4 immunotype strain. The mice were first anaesthetized with an intraperitoneal injection of sodium pentabarbital and then inoculated via a tracheal incision with 50 pl of an agar bead slurry encasing approximately 5 x lo3 c.f.u. of P. aeruginosa. A beaded-tip 22-gauge needle was gently guided to favour inoculation of the left lung. The incision was closed with sterile wound clips. Eight days after the challenge, the mice were killed by cervical dislocation. Protection conferred on CVP-immunized mice was assessed by two methods. First, the lungs were examined macroscopically for the presence of lesions (Staczek et af., 1998) . Lesions were scored as 0 to 4+ based on the scale detailed in Table 2 . An investigator well experienced in macroscopic lung lesion scoring scored the pulmonary lesions. Secondly, the number of P. aeruginosa c.f.u. present in the lungs was quantified as described previously (Staczek et af., 1998 
RESULTS

CPMV-PAE5 elicits P. aeruginosa-specific opsonizing antibody
Mice immunized with CPMV-PAES in either FCA/FIA o r a l u m produced both P. aeruginosa FD2-a n d FD4- specific IgG (Fig. l a a n d b, respectively) , which was absent in mice immunized with w t C P M V in either alum o r FCA/FIA. Immunization with CPMV-PAES in Freund's adjuvants elicited higher titres of both FD2 a n d FD4-specific antibodies t h a n did immunization with CPMV-PAES in alum a t all time-points examined.
CPMV-PAES in Freund's adjuvants elicited specific antibody a s early a s d a y 27 (after t w o immunizations)
whereas antibody w a s not detected in mice vaccinated with CPMV-PAES in alum until after four immunizations, o n d a y 53 (Fig. 1) .
T h e CPMV-PAES-immunized mice produced antisera by day 53 t h a t were highly opsonic for P. aeruginosa (Table 1) . Sera from mice immunized with CPMV-PAES in either FCA/FIA o r alum were significantly more opsonic for FD2 than sera from wtCPMV-immunized groups. T h e degree of opsonization (FCA/FIA > alum) paralleled the titres of FD2-specific IgG present in the sera (Fig. l a ) . T h e level of opsonization of FD2 cells observed with sera from mice immunized with purified protein F in a l u m w a s significantly higher (ratio of 1.76) than with sera f r o m CPMV-PAES-immunized mice when alum w a s used (ratio of 1.35) but not when t P values determined by the unpaired two-tail Student's t-test. FCA/FIA (ratio of 1.93) was used (Table 1) . In parallel studies, sera from mice immunized with CPMV-PAES in either FCA/FIA or alum were also opsonic for FD4 (Table 1) .
CPMV-PAE5 immunization protects mice from P. aeruginosa c ha I I eng e
Mice immunized with CPMV-PAES in either FCA/FIA o r alum were significantly protected against the development of severe ( 2 2 + ) lung lesions (Table 2) .
Following challenge with FD2 in mice in which FCA/FIA was used as the adjuvant, 81.5% of those immunized with wtCPMV had severe lesions, scored as > 2 + , whereas only 33.3% ( P = 0-0004) of mice immunized with CPMV-PAES had severe lesions. Although protection conferred by CPMV-PAES was higher when FCA/FIA was used, significant protection was also seen with CPMV-PAES when alum was used as the adjuvant: 88.9% of mice immunized with wtCPMV had severe lesions, whereas only 64.3% ( P = 0-03) of mice immunized with CPMV-PAES had severe lesions. Similar levels of protection from FD4 challenge were also seen in mice immunized with CPMV-PAES in FCA/FIA or alum (Table 2) . A second indicator of protection afforded by the CVPs was the decrease in bacteria Plant virus vaccine against P. aeruginosa present in the lungs of immunized mice 8 d after challenge (Table 3) . When FCA/FIA was used as the adjuvant and mice were challenged with the FD2 strain of P. aeruginosa, the proportion of mice whose lungs yielded no bacterial growth was increased from 26.9% in mice immunized with wtCPMV to 63% ( P = 0.009) in mice immunized with CPMV-PAE5. When CPMV-PAES in alum was used, a higher (approx. double) proportion of the lungs from immunized mice also had no growth compared to mice immunized with wtCPMV in alum, but these differences were not significant (Table  3) . A significantly ( P = 0.028) higher number (61.7%) of mice immunized with CPMV-PAE5 in FCA/FIA and challenged with the FD4 immunotype strain of P. aeruginosa (Table 3) The 5 x lo3 c.f.u. cut-off has been shown previously to represent a 95% decline from the mean number of bacteria found in the lungs of challenged, control mice on day 8 after challenge in this model (Staczek et al., 1998) . Since approximately 5 x lo3 c.f.u. of P. aeruginosa were inoculated into the lungs at the time of challenge, this cut-off also indicates whether the inoculated bacteria were controlled or were capable of establishing an infection that resulted in a substantial increase in bacterial number within the lung.
DISCUSSION
We have demonstrated here that a chimaeric plant virus particle expressing a tandem peptide containing two linear B cell epitopes from O M protein F of P. aeruginosa confers protection upon outbred mice when challenged with P. aeruginosa in a chronic model of pulmonary infection. The protection observed is mediated by the peptide 10 epitope, since immunization with CPMV-PAE5 fails to elicit antibodies to peptide 18 (Brennan et al., 1999b) . The peptide 10 epitope of O M protein F is conserved among the various strains of P. aeruginosa as evidenced by antibodies directed towards peptide 10 reacting at high titre to all strains of P. aeruginosa tested, including strains representing each of the seven Fisher-Devlin immunotypes and over 50 clinical strains 
with CPMV-PAE5 in Freund's adjuvants elicited the production of high titres of both peptide-and whole P. aer2tRil.tosu-specific IgG. The more clinically applicable alum adjuvant was also tested with CPMV-PAE.5 as alum is the only adjuvant currently accepted for human use (Gupka & Siber, 199.5) . T h e titres of P. aeruginosaspecific IgG elicited by CI'MV-PAES, and consequently the levels of P. aerziginosa opsonization and the degree of p r o tec t i on f o 1 1 ow i n g c h a 1 I e ng e , were subs t a n t i a 11 y higher with Freund's adjuvants than with alum. This implies that more effective adjuvants must be sought for use in humans to enhance the immunogenicity of CPMV-PAES.
T h e commonly used carrier molecule keyhole limpet haemocyanin (KLH) has been uscd previously to deliver O M protein F peptides to the immune system of both mice and rats (Gilleland ek . Peptide 10, when coupled t o KLH and given in alum, conferred protection to both rats and mice from P. aeruginosa infection (Gilleland & Gilleland, 199.5; . In these studies, much higher levels of peptide 10 were used for immunization compared to that delivered by CPMV-PAE.5 in this study. Nevertheless, it is impossible to say if CPMV is a more efficient carrier o f these peptides than KLH since there were differences in the immunization regimens and adjuvants used in the different studies. A chimaeric influenza virus expressing the OM protein F peptide 10 also confers protection from P. aeruginosa FD4 challenge in this samc mouse chronic pulmonary infection model (Staczek ct ul., 1998) . T h e levels of protection achieved with the chimaeric influenza virus were lower (55.6% of challenged mice had severe lesions) than with CPMV-PAES given in Freund's adjuvants (44.7 ' / o with severe lesions, described herein). However, again it is difficult to make direct comparisons between the two viruses since the live influenza was ad m i n is t e r ed us i ng a differ e n t i m m u n i z a t i o n regimen and in the absence of adjuvant. Although it is attractive to think that the use of live respiratory viruses, such as influenza virus, to deliver peptide 10 directly to the lung may serve to generate peptide-10-specific antibody in both the upper and lower respiratory tract, protection from P. aertiginosa infection can be achieved using vaccines that elicit protective serum IgG without eliciting specific antibody in the lung . There may also be safety concerns regarding the delivery of live respiratory viruses to patients with chronic lung infections, although live, attenuated influenza viruses have been shown to be safe in CF patients (Gruber et al., 1994) . Such safety concerns would not be a consideration with the use of chimaeric plant virus vaccines in humans.
Although it is clear from the studies described here that for CPMV-PAE5 to function as an effective P. aeruginosa al., 1997) and bacterial (described herein) diseases, make them attractive candidates for development as vaccines against infectious disease agents.
